Lexicon Pharma (LXRX) Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. DFTX
4. IBM
5. META
6. MU
7. DPZ
8. ACN
9. ZENA
10. CNC

Go back to Lexicon Pharma (LXRX) Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

Lexicon Pharma (LXRX) to Resume Trading at 7:45 a.m.

July 30, 2020 7:42 AM EDT

Lexicon Pharma (NASDAQ: LXRX) to Resume Trading at 7:45 a.m.

... More

Lexicon Pharma (LXRX) Misses Q2 EPS by 4c, Revenues Beat

July 30, 2020 7:28 AM EDT

Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.65), $0.04 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $9.2 million versus the consensus estimate of $8.83... More

Lexicon Pharma (LXRX) Announces Sale of XERMELO for $159 Million

July 30, 2020 7:11 AM EDT

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicons rights, title and interest in XERMELO® (telotristat ethyl).

Pursuant to the terms of the agreement, TerSera will pay Lexicon approximately $159 million in cash at closing, which includes a $155 million upfront... More